JP2007515422A - 糖尿病性網膜症および黄斑変性における結晶腔形成の処置のための薬剤 - Google Patents

糖尿病性網膜症および黄斑変性における結晶腔形成の処置のための薬剤 Download PDF

Info

Publication number
JP2007515422A
JP2007515422A JP2006545506A JP2006545506A JP2007515422A JP 2007515422 A JP2007515422 A JP 2007515422A JP 2006545506 A JP2006545506 A JP 2006545506A JP 2006545506 A JP2006545506 A JP 2006545506A JP 2007515422 A JP2007515422 A JP 2007515422A
Authority
JP
Japan
Prior art keywords
composition
pharmacologically active
subject
agent
dithiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006545506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007515422A5 (enExample
Inventor
ロバート エー． ランダーズ，
デイビッド ピー． ビンガマン，
Original Assignee
アルコン，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルコン，インコーポレイテッド filed Critical アルコン，インコーポレイテッド
Publication of JP2007515422A publication Critical patent/JP2007515422A/ja
Publication of JP2007515422A5 publication Critical patent/JP2007515422A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
JP2006545506A 2003-12-22 2004-12-17 糖尿病性網膜症および黄斑変性における結晶腔形成の処置のための薬剤 Pending JP2007515422A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53181103P 2003-12-22 2003-12-22
PCT/US2004/042562 WO2005063249A1 (en) 2003-12-22 2004-12-17 Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration

Publications (2)

Publication Number Publication Date
JP2007515422A true JP2007515422A (ja) 2007-06-14
JP2007515422A5 JP2007515422A5 (enExample) 2007-10-18

Family

ID=34738705

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006545506A Pending JP2007515422A (ja) 2003-12-22 2004-12-17 糖尿病性網膜症および黄斑変性における結晶腔形成の処置のための薬剤

Country Status (9)

Country Link
US (2) US20050137147A1 (enExample)
EP (1) EP1696926A1 (enExample)
JP (1) JP2007515422A (enExample)
AU (1) AU2004308911B2 (enExample)
BR (1) BRPI0417996A (enExample)
CA (1) CA2548146A1 (enExample)
MX (1) MXPA06006862A (enExample)
WO (1) WO2005063249A1 (enExample)
ZA (1) ZA200605378B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018138195A (ja) * 2013-05-02 2018-09-06 レティナ ファウンデーション オブ ザ サウスウエストＲｅｔｉｎａ Ｆｏｕｎｄａｔｉｏｎ Ｏｆ Ｔｈｅ Ｓｏｕｔｈｗｅｓｔ 二層型眼用インプラント
JPWO2020145364A1 (enExample) * 2019-01-09 2020-07-16

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200604862B (en) * 2003-12-22 2007-10-31 Alcon Inc Agents for treatment of glaucomatous retinopathy and optic neuropathy
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
WO2006030907A1 (ja) * 2004-09-16 2006-03-23 Redox Bioscience Inc. 網膜保護剤
AU2006265113A1 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
FR2902326B1 (fr) * 2006-06-20 2008-12-05 Oreal Utilisation de la coumarine, de butylated hydroxyanisole et d'ethoxyquine pour le traitement de la canitie
WO2008016095A1 (en) * 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT
JP2008247898A (ja) * 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20090324740A1 (en) * 2008-06-13 2009-12-31 Albritton Iv Ford D Novel nasal spray
US20110250184A1 (en) * 2008-12-16 2011-10-13 Onconova Therapeutics ,Inc. Methods for determining efficacy of a therapeutic regimen against deleterious effects of cytotoxic agents in human
WO2012009171A2 (en) * 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
CN112716938A (zh) * 2021-02-25 2021-04-30 新疆医科大学 鞣花酸在制备缓解眼组织病变的药物中的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456757A (en) * 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
US4678783B1 (en) * 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
JP3193301B2 (ja) * 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質ｐ１６０
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5681854A (en) * 1995-11-22 1997-10-28 Alcon Laboratories, Inc. Use of aliphatic carboxylic acid derivatives in ophthalmic disorders
US6271224B1 (en) * 1995-12-21 2001-08-07 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
WO1997028130A1 (en) * 1996-02-02 1997-08-07 Nippon Shinyaku Co., Ltd. Isoquinoline derivatives and drugs
US6586425B2 (en) * 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
ES2286834T5 (es) * 1996-08-12 2011-01-31 Mitsubishi Tanabe Pharma Corporation Medicamentos que comprenden un inhibidor de la rho quinasa.
US5759787A (en) * 1996-08-26 1998-06-02 Tularik Inc. Kinase assay
US6573044B1 (en) * 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
US6441033B1 (en) * 1997-12-22 2002-08-27 Alcon Manufacturing, Ltd. 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists
US5958946A (en) * 1998-01-20 1999-09-28 Styczynski; Peter Modulation of hair growth
US6274338B1 (en) * 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
US20010041174A1 (en) * 1998-11-24 2001-11-15 Najam Sharif Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases
US6020383A (en) * 1999-01-11 2000-02-01 Eastman Chemicals Company Method for reducing blood cholesterol and/or blood triglycerides
US7261881B1 (en) * 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
WO2002002190A2 (en) * 2000-07-05 2002-01-10 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
GB0030727D0 (en) * 2000-12-15 2001-01-31 Lumitech Uk Ltd Methods and kits for detecting kinase activity
US6756063B2 (en) * 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
US6884816B2 (en) * 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
TWI335221B (en) * 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
US7199122B2 (en) * 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
WO2003033662A2 (en) * 2001-10-16 2003-04-24 Atherogenics, Inc. Protection against oxidative stress and inflammation by a cytoprotective response element
ATE445405T1 (de) * 2001-12-18 2009-10-15 Brassica Foundation For Chemop Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen
US20030219846A1 (en) * 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
US6747025B1 (en) * 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CSNC200900243036, 医学のあゆみ, 1991, 第１５６巻, ９９８−１００２ *
JPN6010071589, Ｊｏｕｒｎａｌ ｏｆ Ｎｕｔｒｉｔｉｏｎ, 200307, １３３, ９８５−９９１ *
JPN6010071590, Ｃｈｅｍ． Ｐｈａｒｍ． Ｂｕｌｌ．, 1995, ４３（８）, １３８５−１３８７ *
JPN6010071592, Ｎａｔｕｒａｌ Ｍｅｄｉｃｉｎｅ, 1995, ４９（３）, ２６６−２６８ *
JPN6010071593, 医学のあゆみ, 1991, 第１５６巻, ９９８−１００２ *
JPN6010071595, Ｔｈｒｏｍｂｏｓｉｓ ａｎｄ Ｃｉｒｃｕｌａｔｉｏｎ, 2003, １１（３）, ２２７−２３２ *
JPN6010071598, 現代医療, 1993, ２５（１０）, ３３９３−３３９６ *
JPN6010071600, 月刊眼科医療プラクティス, 2002, ８４．眼の光障害, ９０−９２ *
JPN6010071601, Ｊｏｕｒｎａｌ ｏｆ Ｃｅｌｌｕｌａｒ Ｐｈｙｓｉｏｌｏｇｙ, 2001, １８９, ３２３−３３３ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018138195A (ja) * 2013-05-02 2018-09-06 レティナ ファウンデーション オブ ザ サウスウエストＲｅｔｉｎａ Ｆｏｕｎｄａｔｉｏｎ Ｏｆ Ｔｈｅ Ｓｏｕｔｈｗｅｓｔ 二層型眼用インプラント
US10449145B2 (en) 2013-05-02 2019-10-22 Retina Foundation Of The Southwest Two-layer ocular implant
US10881609B2 (en) 2013-05-02 2021-01-05 Retina Foundation Of The Southwest Methods for treating eye disorders using ocular implants
JPWO2020145364A1 (enExample) * 2019-01-09 2020-07-16
WO2020145364A1 (ja) * 2019-01-09 2020-07-16 山田　健一 網膜疾患の治療のための眼内または経口投与用医薬組成物

Also Published As

Publication number Publication date
CA2548146A1 (en) 2005-07-14
US20050137147A1 (en) 2005-06-23
MXPA06006862A (es) 2007-01-26
ZA200605378B (en) 2008-01-30
BRPI0417996A (pt) 2007-04-27
EP1696926A1 (en) 2006-09-06
AU2004308911B2 (en) 2010-08-26
US20100204244A1 (en) 2010-08-12
AU2004308911A1 (en) 2005-07-14
WO2005063249A1 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
US20100204244A1 (en) Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
JP4755599B2 (ja) 緑内障性網膜症および視神経障害の処置のための薬剤
Liu et al. The novel triterpenoid RTA 408 protects human retinal pigment epithelial cells against H2O2-induced cell injury via NF-E2-related factor 2 (Nrf2) activation
Sanz et al. Significant photoreceptor rescue by treatment with a combination of antioxidants in an animal model for retinal degeneration
Rezaie et al. Protective effect of carnosic acid, a pro-electrophilic compound, in models of oxidative stress and light-induced retinal degeneration
Cuervo et al. Autophagy and aging: the importance of maintaining" clean" cells
Voloboueva et al. (R)-α-lipoic acid protects retinal pigment epithelial cells from oxidative damage
US6228889B1 (en) Methods for treatment of conditions associated with lactosylceramide
Ren et al. Vitamin D supplementation rescues simvastatin induced myopathy in mice via improving mitochondrial cristae shape
Lee et al. Cysteamine prevents the development of lens opacity in a rat model of selenite-induced cataract
Miranda et al. CR-6 protects glutathione peroxidase activity in experimental diabetes
Wu et al. Supplementation with antioxidants attenuates transient worsening of retinopathy in diabetes caused by acute intensive insulin therapy
Uçakhan et al. Superoxide dismutase activity in the lens capsule of patients with pseudoexfoliation syndrome and cataract
US20190060298A1 (en) New drug for the treatment and/or prevention of depressive disorders
Zhang et al. Nitro blue tetrazolium staining: a morphological demonstration of superoxide in the rat retina
KR20070015913A (ko) 당뇨병성 망막병증 및 황반 변성에서의 드루젠 형성의치료용 약제
Blows The neurobiology of antidepressants
US20230083417A1 (en) Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia
US20240058308A1 (en) Treatment and prevention of dry macular degeneration
US20050171139A1 (en) Treating psychotic symptoms
Ghosh Molecular and Biochemical Phenotypes Underlying Reactive Astrocytosis in Primary Optic Nerve Head Astrocytes
US20250009692A1 (en) Micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
Efimenko et al. Assessment of the correction of neuroretinal changes using 2-ethyl-6-methyl-3hydroxypyridinium N-acetyltaurinate in the modeling of POAG
Afrose et al. Targeting trophoblast cell mitochondrial dysfunction in preeclampsia via drug repurposing
WO2025049588A1 (en) Novel treatments for optic neuropathies and glaucoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110324